Results 31 to 40 of about 1,321,964 (375)
Sofosbuvir for previously untreated chronic hepatitis C infection.
New England Journal of Medicine, 2013 BACKGROUND In phase 2 trials, the nucleotide polymerase inhibitor sofosbuvir was effective in previously untreated patients with chronic hepatitis C virus (HCV) genotype 1, 2, or 3 infection.
E. Lawitz +23 more
semanticscholar +1 more source
Gastroenterology, 2005 BACKGROUND AND AIMS Transient elastography (FibroScan; Echosens, Paris, France) is a novel, noninvasive, and rapid bedside method to assess liver fibrosis by measuring liver stiffness.
L. Castéra +8 more
semanticscholar +1 more source
Management of chronic hepatitis C [PDF]
Postgraduate Medical Journal, 2005 AbstractHepatitis C virus (HCV) infection is transmitted primarily through percutaneous exposure to blood, and most infections are associated with injection drug use. Progression to chronic HCV occurs in 55% to 86% of infected people, and persistent infection is a major cause of cirrhosis, end stage liver disease, and hepatocellular carcinoma.
V. Lo Re, Jay R. Kostman
openaire +3 more sources
Urinary porphyrin excretion in hepatitis C infection [PDF]
, 1999 A high prevalence of hepatitis C virus infection in porphyria cutanea tarda in some populations suggests a close link between viral hepatitis and alteration of porphyrin metabolism.
Jacob, Karl +2 more
core +1 more source
Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland
Swiss Medical Weekly, 2018 BACKGROUND The introduction of direct acting antivirals (DAAs) for the therapy of chronic hepatitis C (CHC) has revolutionised treatment and marks a paradigm shift in the approach to this disease, rendering interferon-based therapies obsolete.
Jacqueline A. Bachofner +15 more
doaj +1 more source
Breakthroughs in hepatitis C research: from discovery to cure
Nature reviews: Gastroenterology & hepatology, 2022 In the 1970s, an unknown virus was suspected for documented cases of transfusion-associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious transmissible agent was identified and named hepatitis C virus (HCV) and, soon ...
M. Manns, B. Maasoumy
semanticscholar +1 more source
Gastroenterology Research and Practice, 2016 Purpose. Helicobacter pylori is a common gastric disease-inducing pathogen. Although an increasing number of recent studies have shown that H. pylori is a risk factor for liver disease, the potential association between H.
Juan Wang +8 more
doaj +1 more source
Global analysis of a spatiotemporal cellular model for the transmission of hepatitis C virus with Hattaf-Yousfi functional response [PDF]
arXiv, 2021 In this paper, a mathematical analysis of the global dynamics of a partial differential equation viral infection cellular model is carried out. We study the dynamics of a hepatitis C virus (HCV) model, under therapy, that considers both absorption phenomenon and diffusion of virions, infected and uninfected cells in liver. Firstly, we prove boundedness
arxiv
Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis [PDF]
World Journal of Hepatology, 6(10):759-765, 2014, 2014 AIM: To investigate the predictability of interleukin-28B single nucleotide polymorphism rs12979860 with respect to sustained virological response (SVR) in chronically hepatitis C virus (HCV) genotype-1 patients treated with a protease-inhibitor and pegylated interferon-$\alpha$ (Peg-INF-$\alpha$) based triple-therapy.
arxiv +1 more source
Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort [PDF]
, 2011 Background Liver function tests (LFTs) are ordered in large numbers in primary care, and the Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS) study was set up to assess their usefulness in patients with no pre-existing or self ...
AA Butt +52 more
core +3 more sources